These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 25531387

  • 21. Degradable starch microspheres versus ethiodol and doxorubicin in transarterial chemoembolization of hepatocellular carcinoma.
    Niessen C, Unterpaintner E, Goessmann H, Schlitt HJ, Mueller-Schilling M, Wohlgemuth WA, Stroszczynski C, Wiggermann P.
    J Vasc Interv Radiol; 2014 Feb; 25(2):240-7. PubMed ID: 24291001
    [Abstract] [Full Text] [Related]

  • 22. Response Evaluation Criteria in Solid Tumors (RECIST) criteria are superior to European Association for Study of the Liver (EASL) criteria at 1 month follow-up for predicting long-term survival in patients treated with transarterial chemoembolization before liver transplantation for hepatocellular cancer.
    Shuster A, Huynh TJ, Rajan DK, Marquez MA, Grant DR, Huynh DC, Jaskolka JD.
    J Vasc Interv Radiol; 2013 Jun; 24(6):805-12. PubMed ID: 23562641
    [Abstract] [Full Text] [Related]

  • 23. Transarterial chemoembolization with gelatin sponge microparticles for barcelona clinic liver cancer Stage C and large hepatocellular carcinoma: Initial clinical experience.
    Zhou J, Liu Y, Ren Z, Zhang Y, Zhang M.
    J Cancer Res Ther; 2017 Jun; 13(5):767-772. PubMed ID: 29237901
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Bridging Hepatocellular Carcinoma to Transplant: Transarterial Chemoembolization Response, Tumor Biology, and Recurrence after Transplantation in a 12-Year Transplant Cohort.
    Sandow T, Pavlus J, Field D, Lacayo E, Cohen E, Lynskey G, Caridi T, Buckley D, Cardella J, Kallakury B, Spies J, Kim AY.
    J Vasc Interv Radiol; 2019 Jul; 30(7):995-1003. PubMed ID: 31109853
    [Abstract] [Full Text] [Related]

  • 26. Islet cell liver metastases: assessment of volumetric early response with functional MR imaging after transarterial chemoembolization.
    Li Z, Bonekamp S, Halappa VG, Corona-Villalobos CP, Pawlik T, Bhagat N, Reyes D, Lai H, Geschwind JF, Kamel IR.
    Radiology; 2012 Jul; 264(1):97-109. PubMed ID: 22627602
    [Abstract] [Full Text] [Related]

  • 27. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma.
    Riaz A, Miller FH, Kulik LM, Nikolaidis P, Yaghmai V, Lewandowski RJ, Mulcahy MF, Ryu RK, Sato KT, Gupta R, Wang E, Baker T, Abecassis M, Benson AB, Nemcek AA, Omary R, Salem R.
    JAMA; 2010 Mar 17; 303(11):1062-9. PubMed ID: 20233824
    [Abstract] [Full Text] [Related]

  • 28. Functional magnetic resonance imaging response of targeted tumor burden and its impact on survival in patients with hepatocellular carcinoma.
    Corona-Villalobos CP, Halappa VG, Bonekamp S, Eng J, Reyes D, Cosgrove D, Rastegar N, Pan L, Pawlik TM, Kamel IR.
    Invest Radiol; 2015 Apr 17; 50(4):283-9. PubMed ID: 25396692
    [Abstract] [Full Text] [Related]

  • 29. EASL- and mRECIST-evaluated responses to combination therapy of sorafenib with transarterial chemoembolization predict survival in patients with hepatocellular carcinoma.
    Liu L, Wang W, Chen H, Zhao Y, Bai W, Yin Z, He C, Jia J, Yang M, Xia J, Fan D, Han G.
    Clin Cancer Res; 2014 Mar 15; 20(6):1623-31. PubMed ID: 24493832
    [Abstract] [Full Text] [Related]

  • 30. Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation.
    Kim BK, Kim KA, Park JY, Ahn SH, Chon CY, Han KH, Kim SU, Kim MJ.
    Eur J Cancer; 2013 Mar 15; 49(4):826-34. PubMed ID: 22995582
    [Abstract] [Full Text] [Related]

  • 31. Evaluation of HCC response to locoregional therapy: Validation of MRI-based response criteria versus explant pathology.
    Gordic S, Corcuera-Solano I, Stueck A, Besa C, Argiriadi P, Guniganti P, King M, Kihira S, Babb J, Thung S, Taouli B.
    J Hepatol; 2017 Dec 15; 67(6):1213-1221. PubMed ID: 28823713
    [Abstract] [Full Text] [Related]

  • 32. Unresectable Intrahepatic Cholangiocarcinoma: Multiparametric MR Imaging to Predict Patient Survival.
    Pandey A, Pandey P, Aliyari Ghasabeh M, Najmi Varzaneh F, Shao N, Khoshpouri P, Zarghampour M, Fouladi DF, Liddell R, Kamel IR.
    Radiology; 2018 Jul 15; 288(1):109-117. PubMed ID: 29584595
    [Abstract] [Full Text] [Related]

  • 33. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients.
    Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, Matsuyama Y, Nakanuma Y, Kojiro M, Makuuchi M, Yamaoka Y, Liver Cancer Study Group of Japan.
    Gastroenterology; 2006 Aug 15; 131(2):461-9. PubMed ID: 16890600
    [Abstract] [Full Text] [Related]

  • 34. Conventional Ethiodized Oil Transarterial Chemoembolization for Treatment of Hepatocellular Carcinoma: Contemporary Single-Center Review of Clinical Outcomes.
    Casadaban LC, Minocha J, Bui JT, Knuttinen MG, Ray CE, Gaba RC.
    AJR Am J Roentgenol; 2016 Mar 15; 206(3):645-54. PubMed ID: 26901023
    [Abstract] [Full Text] [Related]

  • 35. Interobserver agreement of semi-automated and manual measurements of functional MRI metrics of treatment response in hepatocellular carcinoma.
    Bonekamp D, Bonekamp S, Halappa VG, Geschwind JF, Eng J, Corona-Villalobos CP, Pawlik TM, Kamel IR.
    Eur J Radiol; 2014 Mar 15; 83(3):487-96. PubMed ID: 24387824
    [Abstract] [Full Text] [Related]

  • 36. Immediate post-doxorubicin drug-eluting beads chemoembolization Mr Apparent diffusion coefficient quantification predicts response in unresectable hepatocellular carcinoma: A pilot study.
    Kokabi N, Camacho JC, Xing M, Edalat F, Mittal PK, Kim HS.
    J Magn Reson Imaging; 2015 Oct 15; 42(4):981-9. PubMed ID: 25683022
    [Abstract] [Full Text] [Related]

  • 37. Lack of response after initial chemoembolization for hepatocellular carcinoma: does it predict failure of subsequent treatment?
    Georgiades C, Geschwind JF, Harrison N, Hines-Peralta A, Liapi E, Hong K, Wu Z, Kamel I, Frangakis C.
    Radiology; 2012 Oct 15; 265(1):115-23. PubMed ID: 22891361
    [Abstract] [Full Text] [Related]

  • 38. Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging.
    Kamel IR, Liapi E, Reyes DK, Zahurak M, Bluemke DA, Geschwind JF.
    Radiology; 2009 Feb 15; 250(2):466-73. PubMed ID: 19188315
    [Abstract] [Full Text] [Related]

  • 39. Identifying enhancement-based staging markers on baseline MRI in patients with colorectal cancer liver metastases undergoing intra-arterial tumor therapy.
    Ghani MA, Fereydooni A, Chen E, Letzen B, Laage-Gaupp F, Nezami N, Deng Y, Gan G, Thakur V, Lin M, Papademetris X, Schernthaner RE, Huber S, Chapiro J, Hong K, Georgiades C.
    Eur Radiol; 2021 Dec 15; 31(12):8858-8867. PubMed ID: 34061209
    [Abstract] [Full Text] [Related]

  • 40. [Comparison of hepatic resection and transarterial chemoembolization for hepatocellular carcinoma within the Milan criteria].
    Guo Z, Xiang B, Zhang J, Jiang J, Li L.
    Zhonghua Yi Xue Za Zhi; 2014 May 27; 94(20):1526-9. PubMed ID: 25146737
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.